...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen
【24h】

Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen

机译:沙眼衣原体多态性膜蛋白D是一种常见的泛中和抗原

获取原文
获取原文并翻译 | 示例
           

摘要

Infections caused by the obligate intracellular pathogen Chlamydia trachomatis have a marked impact on human health. C. trachomatis serovariants are the leading cause of bacterial sexually transmitted disease and infectious preventable blindness. Despite decades of effort, there is no practical vaccine against C. trachomatis diseases. Here we report that all C. trachomatis reference serotypes responsible for sexually transmitted disease and blinding trachoma synthesize a highly conserved surface-exposed antigen termed polymorphic membrane protein D (PmpD). We show that Ab specific to PmpD are neutralizing in vitro. We also present evidence that Ab against serovariable-neutralizing targets, such as the major outer membrane protein, block PmpD neutralization. This finding suggests that a decoy-like immune evasion strategy may be active in vivo whereby immunodominant type-specific surface antigens block the neutralizing ability of species-common PmpD Ab. Collectively, these results show that PmpD is a previously uncharacter-ized C trachomatis species-common pan-neutralizing target. Moreover, a vaccine protocol using recombinant PmpD to elicit neutralizing Ab in the absence of immunodominant type-specific Ab might be highly efficacious and surpass the level of protection achieved through natural immunity.
机译:专一的细胞内病原体沙眼衣原体引起的感染对人类健康有显着影响。沙眼衣原体血清变异体是细菌性传播疾病和可预防传染性失明的主要原因。尽管经过数十年的努力,仍没有针对沙眼衣原体疾病的实用疫苗。在这里,我们报告所有负责性传播疾病和致盲性沙眼的沙眼衣原体参考血清型都合成了高度保守的表面暴露抗原,称为多态性膜蛋白D(PmpD)。我们表明,特异性针对PmpD的抗体在体外被中和。我们还提供证据表明,抗血清变中和目标(例如主要外膜蛋白)的Ab会阻止PmpD中和。这一发现表明,诱饵样免疫逃逸策略可能在体内很活跃,从而免疫优势的类型特异性表面抗原阻断了物种常见的PmpD Ab的中和能力。总的来说,这些结果表明,PmpD是以前未表征的沙眼衣原体物种-常见的泛中和目标。此外,在没有免疫优势型特异性抗体的情况下,使用重组PmpD诱导中和抗体的疫苗方案可能非常有效,并超过了通过自然免疫获得的保护水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号